Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03764774 · ClinicalTrials.gov registry record · Phase 1
A Study of LY3463251 in Healthy Participants
A Phase 1 study, sponsored by Eli Lilly and Company.
- Terminated
- Registry status
- Phase 1
- Development phase
- 118
- Enrollment target
NCT03764774 is a Phase 1 study that was terminated before completion, run by Eli Lilly and Company. The registered enrollment target is 118 participants.
The verdict
NCT03764774, a Phase 1 study, was terminated before completion, sponsored by Eli Lilly and Company.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 118 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety and tolerability (side effects) of single (Part A) and multiple (Part B) doses of the study drug when it is administered subcutaneously (under the skin) into the abdomen. This is a two-part study. Participants will enroll in only one part. For each participant, Part A will last about 10 weeks and Part B will last about 23 weeks, including screening.
Interventions
- DRUG Placebo
- DRUG LY3463251
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 118 participants |
| Start Date | 2018-12-06 |
| Est. Completion | 2020-12-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03764774
The ClinicalTrials.gov registry entry for NCT03764774 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 118 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03764774 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03764774 about?
NCT03764774 is a clinical study titled "A Study of LY3463251 in Healthy Participants". The purpose of this study is to evaluate the safety and tolerability (side effects) of single (Part A) and multiple (Part B) doses of the study drug when it is administered subcutaneously (under the skin) into the abdomen. This is a two-part study. Participants will enroll in only one part. For eac...
What is the current status of trial NCT03764774?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 118 participants. The study started on 2018-12-06. Estimated completion is 2020-12-07.
What interventions are being tested in trial NCT03764774?
The interventions under investigation include: Placebo (DRUG), LY3463251 (DRUG).
Who is sponsoring clinical trial NCT03764774?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.